menu
    • menu
    [{"orgOrder":0,"company":"Idience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"IDX-1197","moa":"PARP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Idience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Idience \/ Undisclosed"},{"orgOrder":0,"company":"Idience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"IDX-1197","moa":"PARP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Idience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Idience \/ Undisclosed"},{"orgOrder":0,"company":"Idience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IDX-1197","moa":"PARP","graph1":"Undisclosed","graph2":"Phase I","graph3":"Idience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Idience \/ Undisclosed"},{"orgOrder":0,"company":"Idience","sponsor":"Ildong Pharmaceutical | National OncoVenture","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"NOV140101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Idience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idience \/ Ildong Pharmaceutical | National OncoVenture","highestDevelopmentStatusID":"6","companyTruncated":"Idience \/ Ildong Pharmaceutical | National OncoVenture"}]

    Find Clinical Drug Pipeline Developments & Deals by Idience

    Menu

    Idience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Idience

                            South Korea arrow
                            CTAD25
                            Not Confirmed

                            Idience

                            South Korea arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDX-1197

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Food Effect Study of IDX-1197 in Healthy Subjects

                            Details : IDX-1197 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 24, 2022

                            Lead Product(s) : IDX-1197

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Idience

                            South Korea arrow
                            CTAD25
                            Not Confirmed

                            Idience

                            South Korea arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDX-1197

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in ...

                            Details : IDX-1197 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 27, 2021

                            Lead Product(s) : IDX-1197

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Idience

                            South Korea arrow
                            CTAD25
                            Not Confirmed

                            Idience

                            South Korea arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDX-1197

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors (VASTUS)

                            Details : IDX-1197 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 22, 2019

                            Lead Product(s) : IDX-1197

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Idience

                            South Korea arrow
                            CTAD25
                            Not Confirmed

                            Idience

                            South Korea arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NOV140101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Ildong Pharmaceutical | National OncoVenture

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

                            Details : NOV140101 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 23, 2017

                            Lead Product(s) : NOV140101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Ildong Pharmaceutical | National OncoVenture

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth